Summary Increased expression of alternatively spliced variants of the CD44 family of cell adhesion molecules has been associated with tumour metastasis. In the present study, expression of alternatively spliced variants of CD44 and their cellular distribution have been investigated in human colonic tumours and in the corresponding normal mucosa, in addition to benign adenomatous polyps. The expression of CD44 alternatively spliced variants has been correlated with tumour progression according to Dukes' histological stage. CD44 variant expression was determined by immunohistochemisty using monoclonal antibodies directed against specific CD44 variant domains together with RT-PCR analysis of CD44 variant mRNA expression in the same tissue specimens. We demonstrate that as well as being expressed in colonic tumour cells, the full range of CD44 variants, CD44v2-vlO, are widely expressed in normal colonic crypt epithelium, predominantly in the crypt base. CD44v6, the epitope which is most commonly associated with tumour progression and metastasis, was not only expressed by many benign colonic tumours, but was expressed as frequently in normal basal crypt epithelium as in malignant colonic tumour cells, and surprisingly, was even absent from some metastatic colorectal tumours. Expression of none of the CD44 vanant epitopes was found to be positively correlated with tumour progression or with colorectal tumour metastasis to the liver, results which are inconsistent with a role for CD44 variants as indicators of colonic cancer progression.
CD44 is a widely distributed cell adhesion molecule that has been implicated in the metastasis of epithelial tumours (Giinthert et al., 1991; and lymphomas (Jalkanen et al., 1991; Sy and Guo, 1991) . There are multiple CD44 isoforms generated by alternative splicing of up to 12 exons, leading to the expansion of a basic 'haematopoietic' transcript (CD44s) into a large family of molecules with potentially diverse functions (Screaton et al., 1992) . CD44s is a major cell-surface receptor for hyaluronate and mediates cell -extracellular matrix (ECM) adhesion (Aruffo et al., 1989) , and also lymphocyte trafficking via the lymph node high endothelium (Jalkanen et al., 1988) .
A range of CD44 alternatively spliced variants, the functions of which are unknown, are expressed in low abundance on some cells of epithelial origin (Terpe et al., 1994) , and are also transiently expressed by activated lymphocytes together with CD44s (Koopman et al., 1993) . A link between CD44 expression, tumour progression and metastasis has been suggested by studies demonstrating an up-regulation of CD44s and CD44 variants in certain tumours (Jalkanen et al., 1991; Stamenkovic et al., 1989; Wielenga et al., 1993; Hart et al., 1991) . The most compelling evidence, however, has come from studies employing animal models, in which transfection of rat CD44 cDNAs containing v6 (exon 10) and v7 (exon 11) into non-metastasising cell lines results in creation of a mestastatic phenotype (Giinthert et al., 1991; Rudy et al., 1993) . Metastasis in these models can be inhibited by co-treatment with monoclonal antibodies directed against CD44s (Guo et al., 1994) , or CD44 variant domains (Seiter et al., 1993) . Isoforms of CD44 have been identified in human tumours by either reverse transcription polymerase chain reaction (RT-PCR) or immunohistochemistry Jackson et al., 1992; Hofmann et al., 1991) , and the results suggest that a disruption in the control of the splicing mechanism may occur in transformed cells. The appearance of splice variants of CD44 occurs soon after neoplastic transformation (Kim et al., 1994) , and the expression of the CD44v6 epitope, encoded by exon 10, has been reported to correlate with tumour progression to more advanced stages in colorectal cancer (Wielenga et al., 1993; Mulder et al., 1995) .
The observed expression of restricted epitope domains of CD44 in metastatic tumours is important because it provides the potential for both highly specific screening of tissue biopsies for metastatic potential (Matsumura et al., 1992) and for therapeutic targeting of mestastatic disease. However, recent reports documenting expression of CD44v6 domain in a few normal colonic tissues (Terpe et al., 1994; Fox et al., 1994) and in bladder cancer (Southgate et al., 1995) question the notion that expression of CD44 variants is indicative of mestastatic disease and may imply a more complex biological role for CD44 variants in normal cells as well as in neoplastic cells.
In order to clarify the impact of expression of alternatively spliced CD44 variants on colonic cancer progression, we have undertaken a comprehensive study of CD44 variant expression in a large sample of patients and compared the malignant tumour specimens with corresponding normal colonic mucosa from the same patients. We have included benign adenomatous polyps as as well as tissues representative of the range of colorectal tumour progression through to metastasis. As the best marker for colorectal tumour progression remains the histological stage, we have correlated CD44 variant epitope expression with Dukes' histological stage of the tumour. Reverse transcriptasepolymerase chain reaction (RT-PCR) and exon-specific priming have been employed to identify specific mRNA transcripts expressed and the cellular localisation of the respective CD44 variant domains was studied by immunohistochemistry. Analysis of the expression of each of the CD44 alternatively spliced exons, the epitopes encoded by them and their cellular distribution should provide insight into the significance of CD44 variant expression in colorectal cancer.
Correspondence: TM Northern blot analyses Total RNA was obtained from frozen tissue specimens by the acid/guanidinium thiocyanate method of Chomczynski and Sacchi (1987) . RNA samples (10 ,ug) were electrophoresed on 1.2% denaturing agarose gels containing 1.1% formaldehyde and blotted by capillary diffusion onto Hybond N nylon membranes (Amersham, Castle Hill, Australia). The membranes were hybridised essentially as described (Antalis and Dickinson, 1992 ) and washed to a final stringency of 0.1 x SSC, 0.1% sodium dodecyl sulphate (SDS) at 650C. Probes directed against specific CD44 variant exons were generated by RT-PCR using total RNA isolated from either the breast cancer cell line ZR75 or a colorectal hepatic metastasis as templates. The amplified DNA was cloned into pGEM-T (Promega, Madison, WI, USA) or pBluescript (Stratagene, La Jolla, CA, USA) and characterised by DNA sequence analysis. Seven CD44 variant probes were obtained and designated pEx6, pEx7, pEx8, pEx9, pExlO, pExl 1, pEx12 -14 ( Figure la) . The CD44 variant plasmid constructs were radiolabelled by the random priming method for Nothern blot analyses (Feinberg et al., 1983) . Specific CD44 sense and antisense riboprobes were transcribed in vitro in the presence of [32P]UTP using SP6, T7 or T3 promoters as appropriate. Blots were reprobed with a radiolabelled oligonucleotide against human 18S rRNA as a measure of total RNA loaded in each lane (Antalis and Dickinson, 1992 (subclass IgM, anti-v8/9) were produced as described (Fox et al., 1994) . Essentially mice were immunised with purified soluble recombinant proteins generated by transfection into COS1 cells of molecular chimaeras comprising CD44 variant exon sequences fused to a CD33 signal sequence and an IgG,-Fc sequence in pCDM8 (Invitrogen, The Netherlands). Vectabond-treated slides (Vector Laboratories, Burlingame, CA, USA) and air dried before fixation in equal parts chloroform/acetone. After rehydration in phosphate-buffered saline (PBS), endogenous peroxidase activity was inhibited with 0.3% hydrogen peroxide and 0.1% sodium azide, and non-specific antibody binding was inhibited by immersion in 4% non-fat skimmed milk powder. Endogenous biotin activity was blocked with 0.1% avidin (Dakopatts, Carpinteria, CA, USA) followed by 0.01% D-biotin. Non-specific antibody binding was further inhibited by preincubating sections with 10% non-immune goat serum. Sections were incubated with primary antibody (or no antibody for control) for 30 min (RT), then biotinylated goat anti-mouse immunoglobulins (Zymed, San Francisco, CA, USA) followed by streptavidin -horseradish peroxidase complex (Zymed). Antigenic sites were demonstrated using 3,3'-diaminobenzidine as chromogen with hydrogen peroxide as substrate. Sections were counterstained with Harris' haematoxylin and mounted in Permount. CD44 expression was assessed with regard to staining intensity (0, 1+, 2 + or 3+), proportion of positive cells (<10%, 10-25%, 25-50%, 50-75% or >75%) and localisation (basal cells, full thickness or scattered cells).
Northern blot analysis of (a) normal colon (N) and primary colonic tumours (P), and (b) normal liver (N) and colorectal liver metastases (LM) using an antisense radiolabelled riboprobe directed against the CD44v8-10 domain (CD44-E). As a control for the amount of RNA loaded in each lane, each blot was reprobed using a radiolabelled oligonucleotide directed against 18S ribsomal RNA.
Statistical analyses
Comparative data were analysed using the Wilcoxon rank sum test.
Results
Northern blot analysis detects CD44v8-10 expression but not CD44v3-7
A total of 37 colon tumours (polyps, n = 6; Dukes' stages A, n = 8; B, n = 10 and C, n = 13) together with matched normal colonic mucosa and 17 liver metastases were examined by Northern blot analysis for expression of CD44 variants using radiolabelled probes directed against exons v3, v6, v7 and v8-10. Three CD44 mRNA transcripts containing v8-10 (2.0 kb, 2.6 kb and 5.6 kb) were detected in all colonic neoplasms including adenomatous polyps and liver metastases. Representative blots are shown in Figure 2a and b. These transcripts were not detected, however, in any specimen of normal colonic mucosa ( Figure 2a ) nor in normal liver tissues ( Figure 2b ) by Northern blot analysis. Northern blots of the same tissue specimens hybridised with variant-specific probes for v3, v6, and v7 resulted in detection of no CD44 transcripts containing these variant exons, even when the membranes were probed using sensitive in vitro generated riboprobes. This may be due to the insensitivity of the Northern blot technique in detecting low abundance mRNA transcripts, which may also be compounded by the use of shorter exon-specific probes in comparison with the larger CD44v8 -10 probe.
Multiple CD44 variant transcripts are detected by reverse transcription-polymerase chain reaction (RT-PCR) In order to detect the presence of low abundance alternatively spliced CD44 mRNA transcripts, RT-PCR was employed using primers flanking the proximal membrane extracellular domain, 3F and 17R (see Figure la) . Multiple amplified products representing different CD44 variant transcripts were detected in all specimens of normal colonic mucosa and tumours analysed from 57 patients. A representative sample is shown in Figure 3a . Both normal and neoplastic colon tissues expressed both the standard (CD44s) (data not shown) and epithelial (CD44E, CD44v8 10) transcripts. In addition, these tisuses expressed slower migrating isoforms of CD44 as shown in Figure 3a .
In order to examine the range of CD44 variant exons expressed in the slower migrating isoforms, a technique termed 'exon-specific' RT -PCR was used. cDNA was amplified by PCR using exon-specific forward primers together with a common reverse primer. 17R, Southern blotted and hybridised with radiolabelled probes spec each CD44 variant exon. Figure 3 shows an example application of this technique to a colorectal liver mei which had demonstrated a range of slower mi isoforms of CD44. Analysis of this tissue specim exon-specific RT-PCR and Southern blotting demon that this tumour specimen expressed the full rai alternatively spliced CD44 variant exons (v2-vlO). In order to investigate CD44 variant exon us randomly selected, individual CD44 mRNA trar contained within the tumour tissues, cDNA synt from four different colonic tumour specimens was I amplified by PCR using primers flanking the pr membrane extracellular domain, and the amplified pi cloned into pGEM-T and sequenced. Figure 5 . In Figure 5a , the normal colonic mucosa expresses CD44 variant exons v4, v5, v7 and v8-vlO in common with the corresponding colonic adenocarcinoma, and the colonic Lane 1 2 S 4 5 b / Figure 3 Southern blot analysis of CD44 variants amplified by RT-PCR. (a) cDNA obtained from RNA isolated from normal colon (N), primary colonic tumours (P), normal liver (NL) and colorectal liver metastases (ML) was amplified using primers flanking the proximal membrane extracellular domains, 3F and 1 7R. Amplification products were separated on 1.2% agarose gels, transferred to nylon membrane and probed with radiolabelled pExl2-14, a plasmid containing the CD44 variant region of CD44E. (b) The 'exon-specific' priming technique to detect specific CD44 variant exon usage in colorectal tissues. cDNA derived from a colorectal liver metastasis containing the full range of CD44 variant exons was amplified using forward primers 6F, 7F, 8F, 9F, lOF, 1 F, 12-14F respectively and the reverse primer 17R. The amplification products were analysed on replicate 1.2% agarose gels and each gel blotted onto a Hybond N nylon membrane. The seven identical blots obtained were each hybridised with a different radiolabelled plasmid containing the CD44 variant exons v2 (pEx6), v3 (pEx7), v4 (pEx8), v5 (pEx9), v7 (pExl 1), or v8 -10 (pEx 12 -14) CD44 variants and colorectal cancer progression DC Gotley et a! 346 adenocarcinoma expresses an additional v3 exon not detected in the normal mucosa. While the specific exon pattern observed in this patient is not necessarily typical (see Figure  5b) , it was commonly observed that CD44 variants expressed in normal mucosa were maintained in corresponding tumours, often with a concomitant increase in one or several additional exons in the tumours only. In some patients, however, a clear progressive increase in exon usage followed progression from normal mucosa to primary adenocarcinoma and subsequently to metastasis in the tissue specimens. For example, in Figure 5b , the primary adenocarcinoma from patient no. 182 shows the appearance of v5 and v7 in addition to v3, v4 and v8-10 detected in the normal mucosa and the additional appearance of v6 in the liver metastasis. Figure 5 CD44 exon usage determined by 'exon-specific' priming RT-PCR of colonic tumours and normal colonic mucosa from two patients. Tissues were subjected to combined exon-specific RT-PCR and Southern blot analysis as described in Figure 3b , and blots were hybridised with radiolabelled plasmid containing v8-10 (pEx12-14) as in the bottom blot in Figure 3b . NC, normal colon; PC, primary colonic carcinoma; LM, colonic liver metastasis. Each of the lanes represents the CD44 variant domains obtained using the common primer 17R and the forward primer indicated. The control sample (C) is the same template cDNA amplified using 17R and 3F primers which covers the entire variant region. Figure 6f . In addition, abundant CD44v6 expression could be found in benign adenomatous polyps as well as malignant colorectal tumours that had metastasised to the liver, as shown in Figure 6h and i respectively. Tables I and II. As shown in Table IB , the results show that the proportion of specimens positive for CD44v6 is similar for benign adenomatous polyps (85%), for advanced colon cancers (Dukes' C, 83%) and for colorectal metastases in the liver (Dukes' D, (80%). Similar proportions of CD44v6 positive specimens are also found in normal mucosal specimens when graded according to the Dukes' stage of the associated tumour (Table IA) . These data do not demonstrate a relationship between CD44v6 expression and colonic tumour progression.
While CD44v6 was detected as commonly in normal mucosa as in colonic tumours, epitopes encoded by CD44v8/ 9, CD44v4/5 and CD44v3 were more frequently detected in colonic tumours compared with normal mucosa (chi-square test: v8/9, 6.64, P=0.01; v6, 0.063, P=0.43; v4/5, 6.7, P=0.001; v3, 4.7, P=0.03 
Discussion
Several studies have suggested an important biological role for CD44 in tumour progression and metastasis, and the potential for the use of CD44 variant expression as a clinicopathological marker of disease progression in colorectal (Wielenga et al., 1993) , breast (Dall et al., 1995) , pancreatic (Takada et al., 1994) and gastric cancers . The finding of a relationship between CD44 variant expression and colorectal cancer progression has not been uniform however (see Finke et al., 1995) (Mulder et al., 1995) (92% vs 67%). The reason for this difference is unclear, although the detection of CD44v6-containing mRNA transcripts by RT-PCR in 85% of lowgrade colorectal tumours in the present study supports the higher positivity rate for this epitope.
The broad extent of CD44 variant expression found in normal colonic mucosa described in this study has not been previously recognised. While CD44v5, v6 and v9 containing transcripts have been detected previously in normal colonic mucosa by RT-PCR (Wielenga et al., 1993) , the respective protein domains have not been demonstrated previously by immunohistochemistry. In the present study, the CD44v6 epitope was detected in as many samples of normal crypt base epithelia as in tumour specimens. CD44 epitopes v3 and v4/5, although more restricted, were expressed in normal colonic mucosa. Since these epitopes were largely confined to the crypt base which is the zone of most rapid cell proliferation, they may play a role in colonic cell proliferation and/or differentiation. Generally, the pattern of CD44 variant exon usage detected by exon-specific RT-PCR in colonic tumours was similar to that seen in the corresponding normal colonic mucosa. This is compatible with the notion that colonic tumour cells may maintain a similar CD44 alternative splicing pattern to the normal mucosa from which they arose, but simply express these epitopes in an overabundance. However, there appear to be exceptions to this rule. In some cases, an entirely different CD44 variant expression pattern or additional exons were detected in the colonic tumour cells compared with the corresponding normal mucosa. In some specimens derived from multiple tumours from the same patients, in which histological differentiation was an obvious variable, different patterns of CD44 variant expression could be detected. This situation is further complicated by the finding that in some specimens CD44 variant expression may be observed on normal colonocytes which are adjacent to the growing tumour margin where, in some cases, the same CD44 variants are not detected in the tumour itself. This curious phenomenon is not explained by current theories of induction of CD44 variant expression in tumours (Hoffman et al., 1993; Jamal et al., 1994) , and implies the involvement of as yet unknown trans-acting mechanisms.
This study has not provided evidence for a simple causeand-effect role for CD44 variant expression and tumour progression. Conversely, the results suggest a complex role for CD44 in colorectal malignancy. The two consistent phenomena demonstrated are a complex array of CD44 splice variants in normal as well as malignant colonic mucosal epithelium, and expression of variable alternatively spliced variant CD44 transcripts in tumours, although particular CD44 variants differ from individual to individual. These findings do not appear to provide support for CD44 variants as a consistent prognostic indicator for colonic tumour progression. There is a need to determine whether CD44 variant expression has a biological role in human epithelial cancers or is simply an epiphenomenon. Studies of the effects of CD44 variant expression on tumour cell invasion and metastasis in model systems will be important for a better understanding of the role of CD44 in tumour progression.
